



Pharmaceutical Services, 2 Franklin Street, Belfast BT2 8DQ  
Telephone No. 028 95 36 0333

To: All Community Pharmacists

21<sup>st</sup> September 2023

Dear colleague

**Medicine Supply Notification: Discontinuation of lixisenatide (Lyxumia®) 20micrograms/0.2ml solution for injection 3ml pre-filled disposable devices**

**Tier 2 – medium impact\***

[Medicines Supply Tool – SPS - Specialist Pharmacy Service – The first stop for professional medicines advice](#)

## Summary

- Lixisenatide (Lyxumia®) 20micrograms/0.2ml solution for injection 3ml pre-filled disposable devices are being discontinued and stock will be exhausted by w/c 18th December 2023.
- Please refer to the Medicines Supply Tool on the Specialist Pharmacy Service (SPS) website for a supply update of other glucagon-like peptide receptor agonists (GLP-1 RA) and clinical guidance on alternative treatment options.
- Information in the National Patient Safety Alert (NatPSA) on the shortage of GLP-1 receptor agonists issued on the 18th July 2023 can be used to guide management of patients switching from lixisenatide.

## Actions Required

- proactively identify and review patients established on lixisenatide (Lyxumia®);
- review the need for a GLP-1 RA and stop treatment if the patient has not achieved beneficial metabolic effect as set out in [NICE NG28](#); and
- refer to the [NatPSA](#) to guide selection of alternative glucose lowering therapy.

## Supporting Information

DHSC will continue to provide updates on GLP-1 RA's stock availability on the [Medicine Supply Tool](#) and designated ['Prescribing available GLP-1 receptor agonists'](#) page on the SPS website.



Pharmaceutical Services, 2 Franklin Street, Belfast BT2 8DQ  
Telephone No. 028 95 36 0333

**Links to further information:**

- [Joint PCDS and ABCD guidance: GLP-1 receptor agonist national shortage](#)
- [BNF lixisenatide](#)
- [SmPC lixisenatide](#)
- [Sanofi – discontinuation notification - Lyxumia](#)